Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of α‐galactosylceramide and interleukin‐18

Nishio, Shoji; Yamada, Naoko; Ohyama, Hideki; Yamanegi, Koji; Nakasho, Keiji; Hara, Masaki; Nakamura, Yoshiteru; Fukunaga, Satoru; Futani, Hiroyuki; Yoshiya, Shinichi; Ueda, Hiroyuki; Taniguchi, Masaru; Okamura, Haruki; Terada, Nobuyuki

doi:10.1111/j.1349-7006.2007.00636.x

Cited by 30 publications

(19 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This hypothesis was addressed in syngeneic tumor models. Intriguingly, whereas daily administration of IL-18 had anti-tumor effects in a syngeneic melanoma model, similar to previous reports [50], a twice/wk schedule of IL-18 showed protumor Human gastric cancer Gastric cancer cell lines in vitro IL-18 mediates production of the proangiogenic factor thrombospondin-1.…”

Section: Tumor-promoting Activities Of Il-18supporting

confidence: 88%

“…In view of its immune-enhancing properties, IL-18 has been investigated for anti-tumor activity in preclinical models ( Table 1). Administration of rIL-18 mediated melanoma or sarcoma regression in syngeneic mice through the activation of CD4 + T and/or NK cell-mediated responses [50,51]. Several other reports indicate that administration of rIL-18 or Il18 gene transfer has anti-tumor effects in different experimental models (reviewed in ref.…”

Section: Anti-cancer Effects Of Il-18mentioning

confidence: 99%

See 1 more Smart Citation

Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

Fabbi

Carbotti

Ferrini

2014

Journal of Leukocyte Biology

147

103

View full text Add to dashboard Cite

IL-18 is a proinflammatory and immune regulatory cytokine, member of the IL-1 family. IL-18 was initially identified as an IFN-γ-inducing factor in T and NK cells, involved in Th1 responses. IL-18 is produced as an inactive precursor (pro-IL-18) that is enzymatically processed into a mature form by Casp1. Different cells, such as macrophages, DCs, microglial cells, synovial fibroblasts, and epithelial cells, express pro-IL-18, and the production of bioactive IL-18 is mainly regulated at the processing level. PAMP or DAMP molecules activate inflammasomes, which trigger Casp1 activation and IL-18 conversion. The natural inhibitor IL-18BP , whose production is enhanced by IFN-γ and IL-27, further regulates IL-18 activity in the extracellular environment. Inflammasomes and IL-18 represent double-edged swords in cancer, as their activation may promote tumor development and progression or oppositely, enhance anti-tumor immunity and limit tumor growth. IL-18 has shown anti-tumor activity in different preclinical models of cancer immunotherapy through the activation of NK and/or T cell responses and has been tested in clinical studies in cancer patients. However, the dual role of IL-18 in different experimental tumor models and human cancers raises critical issues on its therapeutic use in cancer. This review will summarize the biology of the IL-18/IL-18R/IL-18BP system and will address the role of IL-18 and its inhibitor, IL-18BP, in cancer biology and immunotherapy.

show abstract

Section: Tumor-promoting Activities Of Il-18supporting

confidence: 88%

Section: Anti-cancer Effects Of Il-18mentioning

confidence: 99%

Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

Fabbi

Carbotti

Ferrini

2014

Journal of Leukocyte Biology

147

103

View full text Add to dashboard Cite

show abstract

“…(Tsurumi et al, 2011). IL-18 in combination with alpha-GalCer exerts an antitumor effect on NK cell-sensitive tumors primarily by the direct stimulation of NK cells by IL-18 and the indirect stimulation of NK cells by alpha-GalCer through its activation of NKT cells (Nishio et al, 2008). Interleukin (IL)-18 plays important roles in cancer progression and metastasis.…”

Section: Role Of Il-18 In Chemo Sensitivementioning

confidence: 99%

Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18

Kuppala¹,

Syed²,

Bandaru³

et al. 2012

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Interleukin-18 (IL-18) is an immune-stimulatory cytokine with antitumor activity in preclinical models. It plays pivotal roles in linking inflammatory immune responses and tumor progression and is a useful candidate in gene therapy of lymphoma or lymphoid leukemia. A phase I study of recombinant human IL-18 (rhIL-18) in patients with advanced cancer concluded that rhIL-18 can be safely given in biologically active doses to patients with advanced cancer. Some viruses can induce the secretion of IL-18 for immune evasion. The individual cytokine activity might be potentiated or inhibited by combinations of cytokines. Here we focus on combinational effects of cytokines with IL-18 in cancer progression. IL-18 is an important non-invasive marker suspected of contributing to metastasis. Serum IL-18 may a useful biological marker as independent prognostic factor of survival. In this review we cover roles of IL-18 in immune evasion, metastasis and angiogenesis, applications for chemotherapy and prognostic or diagnostic significance.

show abstract

“…The administration of the proinflammatory cytokine IL-18 led to melanoma regression in syngeneic mice through the activation of CD4 + T and/or natural killer cell-mediated response 4,5. IL-18 inhibits tumor angiogenesis via the induction of the anti-angiogenic chemokines CXCL9 and CXCL10 and the downregulation of angiogenin expression 6,7.…”

Section: Introductionmentioning

confidence: 99%

Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma

Yang

Cao

Liu

et al. 2016

DDDT

View full text Add to dashboard Cite

Conditionally replicating adenoviruses have emerged as novel therapeutic agents for cancer. This study aimed to evaluate synergistic antitumor activity of replication-competent adenovirus armed with interleukin (IL)-18 (ZD55-IL-18) and dacarbazine (DTIC) against melanoma. Melanoma A375 cells or nude mouse tumor xenografts were treated with ZD55-IL-18 alone or together with DTIC. The results showed that ZD55-IL-18 competently replicated in A375 cells and expressed IL-18, and these were not affected by DTIC. ZD55-IL-18 enhanced the cytotoxicity of DTIC accompanied by increased apoptosis. Moreover, ZD55-IL-18 and DTIC synergistically inhibited the growth but promoted the apoptosis of A375 xenografts and inhibited vascular endothelial growth factor expression and lung metastasis in xenografts of nude mice. In conclusion, this is the first study to show synergistic anticancer activity of ZD55-IL-18 and DTIC for malignant melanoma. Our results provide evidence that chemo-gene-viro therapeutic approach has greater potential for malignant cancers than conventional chemotherapy or gene therapy.

show abstract

Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of α‐galactosylceramide and interleukin‐18

Cited by 30 publications

References 49 publications

Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

Context-dependent role of IL-18 in cancer biology and counter-regulation by IL-18BP

Immunotherapeutic Approach for Better Management of Cancer - Role of IL-18

Oncolytic adenovirus expressing interleukin-18 improves antitumor activity of dacarbazine for malignant melanoma

Contact Info

Product

Resources

About